FDA approves neladalkib for ALK-positive lung cancer
-
By
-
Teraya Smith
-
November 18, 2026
-
2 min
By
Teraya Smith
November 18, 2026
The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .
by Mouj Hijazi
October 27, 2026
A splinter injury progressed to finger necrosis in a patient with MDS, despite antibacterial treatment and no clinically apparent systemic dissemination.
October 26, 2026
The accelerated approval adds an immunotherapy option for patients with MSI-H/dMMR stage II/III disease.
by Mouj Hijazi
October 19, 2026